



UCB, Inc. - 1950 Lake Park Drive – Smyrna, Georgia 30080

March 21, 2008

Request to initiate Neupro® down-titration

Dear Healthcare Provider,

Schwarz Pharma, a company of the UCB group, will be recalling Neupro® (rotigotine transdermal system) at the end of April 2008. The product will not be available in the United States after this date. However, patients must first be gradually down-titrated with the current supplies available. Neupro® is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease.

The decision to recall is due to the formation of rotigotine crystals in the patches. When the drug crystallizes, less drug is available to be absorbed through the skin. Therefore, the efficacy of the affected product may vary.

The following actions are necessary:

- 1. Do not initiate any new patients on Neupro®**
- 2. Begin down-titrating all patients currently using Neupro® as per the guidelines in the product label** (reduce by 2 mg/24 hours with a dose reduction preferably every other day)

It is strongly advised that patients do not abruptly discontinue therapy. Abrupt withdrawal of dopamine agonists has been associated with a syndrome resembling neuroleptic malignant syndrome or akinetic crises.

Down-titration should be performed with product that is unaffected or minimally affected as illustrated in picture A. Product as shown in picture B should not be used. (See example pictures and instructions on reverse side).

A "Dear Patient" letter is enclosed; please copy and distribute it to your patients. This patient letter has also been provided to patient support organizations and can be downloaded from the Neupro® website www.neupro.com. In addition, we are advising pharmacists of this situation. A copy of product prescribing information is also enclosed.

UCB will provide instructions regarding the disposition of unused product when the product is recalled.

UCB is committed to keeping open lines of communication. Please notify us of any patients with no treatment alternatives. Do not hesitate to contact your local representative or to call UCB Medical Information directly at 1-800-477-7877 (option 9) if you have any questions. Information will also be publicly available on the Neupro® website.

Thank you for your understanding and assistance.

Sincerely,

A handwritten signature in black ink that reads "Kathleen Bos MD". The signature is written in a cursive, flowing style.

Kathleen Bos, MD
Vice President, U.S. Medical Affairs
UCB, Inc.

A. You may use patches that have this amount of crystals, or less. The exact pattern or location of crystals on a patch may not look exactly like this.



B. Do not use patches that have this amount of crystals. The exact pattern or location of the crystals on a patch may not look exactly like this.

